Clinical Research Directory

Inclusion Criteria: 1. Female patients aged 40 to 75 years. 2. Established diagnosis of type 2 diabetes mellitus for \>= 12 months. 3. Baseline glycated hemoglobin (HbA1c) between 6.5% and 10.0%. 4. Documented history of recurrent urinary tract infections (\>= 2 episodes in the preceding 12 months or \>= 1 episode in the preceding 6 months). 5. Absence of active symptomatic UTI at enrollment, verified by screening urine analysis and culture. 6. Maintained on stable glucose-lowering therapy for at least 3 months prior to enrollment. 7. Willing and able to comply with the 60-day supplementation and 180-day follow-up protocol. 8. Provided written informed consent. Exclusion Criteria: 1. Active, symptomatic urinary tract infection at the time of screening. 2. Known anatomical or functional urinary tract abnormalities (e.g., neurogenic bladder, urinary tract obstruction, indwelling catheter). 3. Severe renal impairment (eGFR \< 30 mL/min/1.73 m2) or end-stage renal disease. 4. Severe hepatic impairment or active malignancy. 5. Routine use of systemic antibiotic prophylaxis for UTI within 30 days prior to screening. 6. Regular intake of cranberry-containing supplements, D-mannose, or commercial probiotic formulations within 30 days prior to enrollment. 7. Known allergy or hypersensitivity to cranberry extracts, proanthocyanidins, or any excipient in the study formulation. 8. Pregnancy, lactation, or women planning pregnancy during the study duration.